136 related articles for article (PubMed ID: 37130758)
21. Increased incidence of prostate cancer in Nigerians.
Ogunbiyi JO; Shittu OB
J Natl Med Assoc; 1999 Mar; 91(3):159-64. PubMed ID: 10203918
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men.
Zlotta AR; Egawa S; Pushkar D; Govorov A; Kimura T; Kido M; Takahashi H; Kuk C; Kovylina M; Aldaoud N; Fleshner N; Finelli A; Klotz L; Sykes J; Lockwood G; van der Kwast TH
J Natl Cancer Inst; 2013 Jul; 105(14):1050-8. PubMed ID: 23847245
[TBL] [Abstract][Full Text] [Related]
23. Incidence of prostate cancer after termination of screening in a population-based randomised screening trial.
Grenabo Bergdahl A; Holmberg E; Moss S; Hugosson J
Eur Urol; 2013 Nov; 64(5):703-9. PubMed ID: 23721957
[TBL] [Abstract][Full Text] [Related]
24. Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden.
Orrason AW; Styrke J; Garmo H; Stattin P
BJU Int; 2023 Apr; 131(4):486-493. PubMed ID: 36088648
[TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2007 and 2013: status from a Danish primary referral center.
Thomsen FB; Mikkelsen MK; Hansen RB; Krug AH; Glenthøj A; Stattin P; Brasso K
Acta Oncol; 2016 Dec; 55(12):1456-1460. PubMed ID: 27333339
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of elevated serum prostate-specific antigen in rural Nigeria.
Ukoli F; Osime U; Akereyeni F; Okunzuwa O; Kittles R; Adams-Campbell L
Int J Urol; 2003 Jun; 10(6):315-22. PubMed ID: 12757603
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic characteristics of lethal prostate cancer.
Helgstrand JT; Røder MA; Klemann N; Toft BG; Brasso K; Vainer B; Iversen P
Eur J Cancer; 2017 Oct; 84():18-26. PubMed ID: 28779631
[TBL] [Abstract][Full Text] [Related]
28. Prostate cancer incidence and newly diagnosed patient profile in Spain in 2010.
Cózar JM; Miñana B; Gómez-Veiga F; Rodríguez-Antolín A; Villavicencio H; ; Cantalapiedra A; Pedrosa E
BJU Int; 2012 Dec; 110(11 Pt B):E701-6. PubMed ID: 22989066
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness.
Storebjerg TM; Høyer S; Kirkegaard P; Bro F; ; Ørntoft TF; Borre M; Sørensen KD
BJU Int; 2016 Oct; 118(4):646-53. PubMed ID: 26779768
[TBL] [Abstract][Full Text] [Related]
30. Need for and relevance of prostate cancer screening in Nigeria.
Akinremi T; Adeniyi A; Olutunde A; Oduniyi A; Ogo C
Ecancermedicalscience; 2014; 8():457. PubMed ID: 25228913
[TBL] [Abstract][Full Text] [Related]
31. The burden of HPV associated cancers in two regions in Nigeria 2012-2014.
Jedy-Agba EE; Dareng EO; Adebamowo SN; Odutola M; Oga EA; Igbinoba F; Otu T; Ezeome E; Bray F; Hassan R; Adebamowo CA
Cancer Epidemiol; 2016 Dec; 45():91-97. PubMed ID: 27780076
[TBL] [Abstract][Full Text] [Related]
32. Prostate cancer in Maiduguri.
Yawe KT; Tahir MB; Nggada HA
West Afr J Med; 2006; 25(4):298-300. PubMed ID: 17402521
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer cognitive-behavioral factors in a West African population.
Odedina FT; Yu D; Akinremi TO; Reams RR; Freedman ML; Kumar N
J Immigr Minor Health; 2009 Aug; 11(4):258-67. PubMed ID: 19051034
[TBL] [Abstract][Full Text] [Related]
34. Phase of care prevalence for prostate cancer in New South Wales, Australia: A population-based modelling study.
Yu XQ; Luo Q; Smith DP; Clements MS; Patel MI; O'Connell DL
PLoS One; 2017; 12(2):e0171013. PubMed ID: 28178275
[TBL] [Abstract][Full Text] [Related]
35. [PSA testing, biopsy and cancer and benign prostate hyperplasia in France].
Tuppin P; Samson S; Fagot-Campagna A; Lukacs B; Alla F; Allemand H; Paccaud F; Thalabard JC; Vicaut E; Vidaud M; Millat B
Prog Urol; 2014 Jul; 24(9):572-80. PubMed ID: 24975792
[TBL] [Abstract][Full Text] [Related]
36. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
37. Knowledge, attitudes and screening practices regarding prostatic diseases among men older than 40 years: a population-based study in Southwest Nigeria.
Ojewola RW; Oridota ES; Balogun OS; Ogundare EO; Alabi TO; Banjo OO; Laoye A; Adetunmbi B; Adebayo BO; Oluyombo R
Pan Afr Med J; 2017; 27():151. PubMed ID: 28904679
[TBL] [Abstract][Full Text] [Related]
38. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
[TBL] [Abstract][Full Text] [Related]
39. [Clinicopathologic characteristics and prognosis of early onset prostate cancer].
Wang Y; Du SJ; Zhang JX; He HY
Zhonghua Bing Li Xue Za Zhi; 2017 Jun; 46(6):373-377. PubMed ID: 28591982
[No Abstract] [Full Text] [Related]
40. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis.
Gandaglia G; Abdollah F; Schiffmann J; Trudeau V; Shariat SF; Kim SP; Perrotte P; Montorsi F; Briganti A; Trinh QD; Karakiewicz PI; Sun M
Prostate; 2014 Feb; 74(2):210-6. PubMed ID: 24132735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
